Shares of Novavax Inc. NVAX slid 6.23% to $6.92 Wednesday, on what proved to be an all-around grim trading session for the ...

“We are evolving our organization’s capabilities and different roles across the company, including those on our leadership ...

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

There is no “the” vaccine. There are at least two mRNA vaccines (Moderna and Pfizer) and a number of different non-mRNA ...

My name is Alec Stranahan, Senior Biotech Analyst covering Novavax at Bank of America. And I'm very pleased to be joined by many members of the senior leadership team at Novavax, including John ...

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

CRISPR Therapeutics announced an agreement with Sirius Therapeutics to develop and commercialize small interfering RNA (siRNA ...

The Centers for Disease Control and Prevention will no longer recommend routine Covid shots for healthy children and pregnant ...